AstraZeneca Bets $2 Billion on Summit Therapeutics' Bispecific Cancer Drug

AstraZeneca is putting $2 billion into Summit Therapeutics. The equity investment, announced after Monday's market close, does more than write a check. It launches a research collaboration aimed at testing drug combinations in gastrointestinal cancers, with room to expand from there.

At the center of the deal sits ivonescimab, Summit's bispecific antibody. The molecule binds two targets at once: PD-1 on T cells and VEGF on cancer cells. That dual mechanism has drawn intense interest across oncology drug development, and AstraZeneca's investment signals it wants a seat at that table.

Ivonescimab was originally developed by China-based Akeso Therapeutics. The drug drew attention after Phase 3 trial results in lung cancer showed it reduced the risk of disease progression or death by 49% compared to Merck's Keytruda, a blockbuster PD-1 inhibitor, in a head-to-head study. That trial, however, ran in China, where Akeso already markets the drug with lung cancer approvals in hand.

Summit's fortunes depend on a different set of data. The company holds rights to ivonescimab in North and South America, Europe, the Middle East, Africa, and Japan, and its case rests on clinical trials conducted outside China. Those results remain pending. Investors betting on Summit are effectively betting that the China data translates to other regions, a proposition that carries real uncertainty.

The ADC Combination Thesis

AstraZeneca brings its own asset to this partnership: sonesitatug vedotin, an experimental antibody drug conjugate known as sone-ve. In July, the company reported that sone-ve met the main goal of a Phase 3 trial, delivering a statistically significant improvement in overall survival in CLDN18.2-positive gastric cancers. Detailed results are due at the European Society for Medical Oncology conference in late October.

That same ESMO meeting will feature data on ivonescimab in biliary tract cancer. Last month, Summit reported preliminary Phase 3 results showing a statistically significant overall survival benefit for ivonescimab plus chemotherapy compared to durvalumab plus chemotherapy, in a pivotal study Akeso conducted in China.

Drug resistance is a known weakness of ADCs. The theory behind pairing them with PD-1/VEGF bispecific antibodies is that the dual mechanism reshapes the tumor microenvironment, making it more receptive to ADC activity and potentially overcoming that resistance. It's a compelling scientific rationale, but it remains a rationale. Combination data specific to sone-ve and ivonescimab together does not yet exist.

This is not an isolated bet. AbbVie committed $650 million to a deal in this space in January. Bristol Myers Squibb partnered with BioNTech last June. Merck acquired a bispecific antibody through its Lanova deal in late 2024. Pfizer struck its own PD-1/VEGF bispecific agreement with 3SBio in May. Crescent Biopharma licensed a Kelun Biopharma ADC late last year specifically to pair with its own PD-1/VEGF bispecific antibody. The pattern is clear: multiple large pharma companies and biotechs are racing to secure a position in this mechanism class before the competitive window closes.

Susan Galbraith, AstraZeneca's executive vice president for oncology hematology R&D, framed the deal in strategic terms. "A core pillar of our oncology strategy is to broaden the reach of our ADC portfolio as the backbone of treatment across tumor types with combinations alongside next-generation immunotherapies," she said in a prepared statement. The Summit deal also includes a non-binding memorandum of understanding permitting additional trials pairing ivonescimab with other AstraZeneca cancer drugs, including other ADCs beyond sone-ve.

Not every analyst sees this as a full commitment. Leerink Partners analyst Daina Graybosch called the deal "more tepid than an outright acquisition" in a research note. She noted the structure leaves AstraZeneca two paths forward. It could deepen its investment in Summit as trial data mature. Or it could use the collaboration to study the mechanism, then walk away and license a competing bispecific antibody from another company entirely.

That second scenario has precedent. Graybosch pointed to Merck's licensing of a TROP2-targeting ADC from Kelun, a deal that followed Merck's review of clinical data generated through a collaboration with AstraZeneca and Gilead Sciences. In other words, joint trials sometimes function as due diligence rather than a prelude to permanent partnership.

The mechanics of the equity investment are specific. AstraZeneca will buy roughly 108,955 shares of Summit at $18.36 each, an 18.6% premium over Monday's closing price. Both companies will jointly fund the planned clinical trials, which they expect AstraZeneca to sponsor. Each retains full development and commercialization rights to its own molecule. The transaction is expected to close by the end of this week.

Investment Implications

For AstraZeneca, the $2 billion outlay buys optionality more than certainty. It secures early access to a late-stage bispecific antibody candidate without requiring a full buyout, while preserving the right to license a rival compound if Summit's data disappoint or a competitor's asset looks stronger. That flexibility cuts both ways for Summit shareholders. The premium purchase price and pharma validation offer near-term support, but the structure does not guarantee AstraZeneca's long-term commitment.

The real catalyst sits at ESMO in late October, when detailed sone-ve gastric cancer data and ivonescimab biliary tract cancer results reach the public. Those readouts, combined with the pending outside-China trials Summit is running for ivonescimab, will determine whether this collaboration deepens into something more permanent or serves as the kind of exploratory step Graybosch describes. Investors should watch for signs of expanded trial commitments or additional equity purchases as markers that AstraZeneca's confidence is solidifying rather than merely testing the waters.